UNFOLD Study Egypt

Study identifier:D133FR00199

ClinicalTrials.gov identifier:NCT06188494

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Multicenter, Observational, Secondary data collection, Retrospective, National Study to Assess the Prevalence of HER2-low Breast Cancer Among Patients Previously Diagnosed with Unresectable and/or Metastatic HER2-Negative Breast Cancer in Egypt – UNFOLD

Medical condition

Breast Cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

400

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 13 May 2024
Estimated Primary Completion Date: 30 Nov 2024
Estimated Study Completion Date: 30 Nov 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Dec 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria